In vitro and in vivo activation of astrocytes by amyloid-β is potentiated by pro-oxidant agents by García-Matas, Silvia et al.
  1  
1 
 Title: 
In vitro and in vivo activation of astrocytes by amyloid β is potentiated by pro-oxidant 
agents 
 
Authors and affiliation: 
S García-Matas1, N de Vera1, A Ortega Aznar2, JM Marimon3, A Adell4, AM Planas1, R 
Cristòfol1, C Sanfeliu1
 
. 
1. Dept. Isquèmia Cerebral i Neurodegeneració, Institut d’Investigacions Biomèdiques 
de Barcelona (IIBB), CSIC-IDIBAPS, E-08036 Barcelona, Spain. 
2. Dept. Anatomia Patològica (Neuropatologia), Hospital Universitari Vall d’Hebron, E-
08035 Barcelona. 
3. Unitat d’Experimentació Animal de Psicologia, Universitat de Barcelona, E-08035 
Barcelona. 
4. Departament de Neuroquímica i Neurofarmacologia, IIBB, CSIC-IDIBAPS, E-08036 
Barcelona. 
 
 
Running title: 
Amyloid β activated astrocytes 
 
 
 
 
Correspondence: 
Dr Coral Sanfeliu 
Dept. Brain Ischemia and Neurodegeneration 
IIBB, CSIC-IDIBAPS 
c/Rosselló 161, 6th floor 
08036 Barcelona, Spain 
Tel. (+34) 933638338 
Fax. (+34) 933638301 
coral.sanfeliu@iibb.csic.es 
 
  2  
2 
 
Abstract:  
Alzheimer’s disease (AD) is a devastating age-related neurodegenerative disease. Age is 
main risk factor for sporadic AD, which is the most prevalent type. Amyloid-β peptide 
(Aβ) neurotoxicity is the proposed first step in a cascade of deleterious events leading to 
AD pathology and dementia. Glial cells play an important role in these changes. 
Astrocytes provide vital support to neurons and modulate functional synapses. 
Therefore, the toxic effects of Aβ on astrocytes promote neurodegenerative changes that 
could lead to AD. Aging reduces astrocyte antioxidant defense and induces oxidative 
stress. We studied the effects of Aβ42 on cultures of human astrocytes in the presence or 
absence of the following pro-oxidant agents: buthionine sulfoximine (BSO), a 
glutathione synthesis inhibitor, and FeSO4, which liberates redox active iron. Pro-
oxidant conditions potentiated Aβ toxicity, as shown by the generation of free radicals, 
inflammatory changes and apoptosis. A similar treatment was assayed in rats in vivo. A 
combination of Αβ40 and Αβ42 or Aβ42  alone was infused intracerebroventricularly for 4 
weeks. Other animal groups were also infused with BSO and FeSO4
 
. A long-term 
analysis that ended 4 months later showed higher cognitive impairment in the Morris 
water maze task, which was induced by Aβ plus pro-oxidant agent treatments. Pro-
oxidant agents also potentiate brain tissue pathology. This was demonstrated in 
histological studies that showed highly increased astrocyte reactivity in AD-vulnerable 
areas, Aβ deposits and oxidative damage of AD-sensitive hippocampal neurons. To 
increase understanding of AD, experimental models should be used that mimic age -
related brain changes, in which age-related oxidative stress potentiates the effects of Aβ. 
Key words: human astrocyte cultures, rat model of Alzheimer’s disease, amyloid-β 
peptide, iron, oxidative stress, inflammation 
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Introduction 
Alzheimer’s disease (AD) is the main age-related neurodegenerative disease. Despite 
intensive research, its trigger mechanisms are elusive and no cure is available yet. At 
present, the most widely accepted theory is the amyloid cascade hypothesis which 
postulates a brain increase in amyloid-β peptide (Aβ) as the main causative agent of a 
cascade of molecular and cellular events leading to neurodegeneration and dementia 
In sporadic AD, which accounts for 95 % of AD cases, the main risk factor is age. Age 
also has an influence on familial AD, as the disease always occurs during late maturity. 
There is likely to be an interaction between cell environment, metabolism of amyloid-β 
protein precursor (AβPP) and Aβ accumulation in AD throughout brain aging. One 
possible environmental influence is oxidative stress. Harman’s free radical theory of 
aging [4] established the basis for discovering how oxidative damage accumulates in 
cells and leads to their deterioration with advancing age. Neurons are highly sensitive to 
oxidative damage because they have high metabolic activity, a high content of 
polyunsaturated fats and other oxidizable substrates, and relatively low antioxidant 
defenses [5]. This sets the conditions for increased Aβ generation in selectively 
vulnerable neurons in the aging brain. Pro-oxidant or oxidant agents have been shown 
to generate Aβ by increasing β-secretase and γ-secretase activity [6-9]. However, Aβ 
itself can induce the production of hydrogen peroxide or other reactive oxygen species 
(ROS) in concert with the redox active metal ions Fe
[1]. 
Genetic and environmental influences induce an excess of Aβ generation by sensitive 
neurons during the metabolism of its precursor protein. Both intracellular and 
extracellular Aβ cause a number of interrelated derangements, including inflammation, 
facilitation of tau hyperphosphorylation, disruption of mitochondrial and proteasomal 
function, oxidative stress, alteration of calcium signaling and impairment of synaptic 
function [2, 3]. The main pathological hallmarks of the disease, amyloid plaques and 
fibrillary tangles, together with neuronal loss, are considered the ultimate consequences 
of this cascade of events. 
2+ or Cu+ [10,11]. Iron and other 
biometals such as copper and zinc interact with Aβ and cause its aggregation [12,13]. 
Iron also interacts with AβPP at the translational level, as ΑβPP is post-transcriptionally 
regulated by iron regulatory proteins (IRPs) through a 5’UTR iron-responsive element 
(IRE) [14]. In brain aging, there is dysregulation of metal homeostasis and metals may 
accumulate in brain areas that are prone to neurodegeneration, which influences AD 
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pathology [11, 15-17]. Accumulated iron in the AD brain appears to contribute 
significantly to the oxidative damage that is one of the earliest pathological changes in 
AD [18, 19].  
In addition to neurons, astroglia are major components of the brain. Astrocytes have an 
important role, beyond the provision of metabolic and structural support for 
neurons.They are involved in Ca2+ signaling, gliotransmission and modulation of 
synaptogenesis [20-22]. Their involvement in cognitive brain function, either through 
neuronal support function or by direct information processing in the tripartite synapsis 
[23], adds relevance to their role in AD development. We previously demonstrated that 
aged astrocytes in vitro and astrocytes cultured from the senescence-accelerated mouse 
model SAMP8 have higher oxidative stress, lower antioxidant defense and a decreased 
capacity to support neuron survival [24, 25]. In addition, we detected proteomic changes 
that are indicative of brain AD-like functional deterioration in both astrocytes and 
neurons from SAMP8 [26]. Therefore, aged astrocytes may not effectively defend 
neurons against the development of AD. Indeed, Aβ triggers a neuroprotective response 
in healthy astrocytes, which involves either phagocytosis and degradation of Aβ [27] or 
increased secretion of neuroprotective factors [28, 29]. In contrast, aged astrocytes may 
have deficits in Aβ clearance and neurotrophic support and may even secrete pro-
inflammatory agents, derived from their basal level of activation [30]. Accordingly, 
astrocytes from SAMP8 mice showed a higher level of reactive gliosis after Aβ42
The aim of this study was to analyze how increased oxidative stress in the aging brain 
contributes to the development of AD pathology, with an emphasis on astrocytes. 
Human astrocyte cultures were used as an in vitro model to study the astrocyte response 
to Aβ
 
treatment than cultures from non-senescent mice [31]. 
42 in a pro-oxidant environment. This environment was created by glutathione 
depletion with buthionine sulfoximine (BSO) and the redox active iron compound 
FeSO4. Next, we used a validated AD rat model with a four-week chronic 
intracerebroventricular (icv) infusion of a mixture of Aβ40 and Aβ42 [32]. In this in vivo 
model, we assayed the long-term effects of glutathione depletion and reactive iron with 
Aβ, BSO and FeSO4
 
 doses according to a previous short-term study [33].  
 
Materials and methods 
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Human astrocyte cultures 
Human cortical brain tissue was obtained from normal, legally aborted fetuses at 14-16 
weeks of gestation. Permission to use human fetal tissue was obtained from the ethics 
committee of the Spanish National Research Council (CSIC). Cultures of human 
cerebral cortical astrocytes were prepared as described elsewhere [34]. Cell culture 
media and reagents were purchased from Gibco (Invitrogen, Paisley, United Kingdom). 
Plastic culture plates were from Nunc (Roskilde, Denmark). Briefly, after enzymatic 
digestion and dissociation of tissue samples, cells were suspended in minimum Eagle’s 
medium (MEM) supplemented with 5% heat-decomplemented horse serum, 0.5% w/v 
D-glucose, 2 mM glutamine 200 µg/mL gentamycin and 0.5 µg/L fungizone. Cells were 
seeded in poly-L-lysine-coated culture plates and maintained in a humidified CO2 
incubator at 37ºC. Fresh medium was added weekly until the end of the study. To obtain 
highly enriched astrocyte cultures, cells were seeded at 2-3x106 cells/ml and submitted 
to limited in vitro passage. For this purpose, 1 month old cultures were extensively 
washed with PBS, mildly trypsinized in the presence of 0.02% EDTA, and reseeded at 
1x106 cells/ml. Another passage was performed 2 weeks later. Alternatively, primary 
cultures were frozen in liquid nitrogen (cryoprotected with 10% DMSO in serum) at the 
first passage, and thawed later on to grow the highly enriched astrocyte cultures. 
Astrocytes were seeded for experiments at 0.5x106 cells/ml (1.5x105 cells/cm2
 
) in 96-
well plates and used after 2-3 days. Cultures consisted of 90–95% astrocytes, 5–10% 
microglia and 0.1–1% oligodendroglia as reported elsewhere [34]. All reagents used in 
the study were from Sigma-Aldrich, Inc. (St. Louis, MO), unless otherwise stated. 
Hydroperoxide generation assay 
Oxidative stress in astrocyte cultures was studied using 2’,7’-dichlorofluorescein 
diacetate (DCFH-DA, Molecular Probes, Invitrogen) to determine intracellular 
hydroperoxide generation [34]. The non-fluorescent probe DCFH-DA freely permeates 
the cell membrane. Once the DA Group has been hydrolyzed by cell esterases, DCFH 
may be oxidized to the fluorescent 2’,7’-dichlorofluorescein (DCF). Either control 
cultures or cultures that had been pre-incubated 24 h with BSO 1mM were washed in 
HEPES and loaded with 10 μM of DCFH-DA from a stock solution of 2 mM in 
methanol. After 20 min of incubation at 37ºC cells were washed again in HEPES and 
basal fluorescence was measured at 485 nm excitation/530 nm emission in a plate 
reader (Spectramax Gemini XS, Molecular Devices, MDS, Sunnivale, CA). Then, the 
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agents FeSO4 and Aβ42 were added to the corresponding wells at concentrations of 25 
μM and 20 μM, respectively. BSO was added to the pre-incubated wells when the probe 
was loaded and during the incubation with FeSO4 and Aβ42. Fibrillar Aβ42 
 
was 
dissolved in DMSO [35]. The corresponding controls were incubated with the vehicle. 
After 4 h, fluorescence was measured again. The increase in intracellular ROS was 
quantified from a standard curve of DCF in methanol (0.5-100 nM) and expressed as the 
DCF generated per μg of protein. The concentration of proteins was determined by the 
Bradford method. Aβ peptides in the study were from Bachem (Bubendorf, 
Switzerland).  
Nitrite assay 
Nitric oxide synthesis by activated astrocyte cultures was measured by the colorimetric 
Griess reaction that detects nitrite (NO2–), a stable reaction product of nitric oxide (NO) 
and molecular oxygen. Astrocytes were treated with 10 ng/ml of interleukin-1β, 10 
ng/ml of interferon-γ, or both. Next, experiments were performed with 1mM BSO, 10 
µΜ FeSO4 and 5 µΜ Aβ42
 
. Whenever present, BSO was additionally preincubated for 
24 h. Agents were directly added to the culture media in the wells. After 3 days of 
exposure to the treatments, 50 µL aliquots of culture supernatants were incubated with 
50 µL Griess reagent (1% sulphanilamide, 0.1% N-(1-naphthyl)ethylenediamine 
dihydrochloride and 5% phosphoric acid) at room temperature for 10 min and the 
optical density at 540 nm was then determined using a microplate reader (iEMS Reader 
MF, Labsystems, Finland). The nitrite concentration was determined from a sodium 
nitrite standard curve (1-50 µM). 
Immunocytochemistry and cell death staining 
Morphological changes caused by exposure to cytokines or to BSO, FeSO4, and Aβ42 
for 3 days were analyzed in astrocytes that were immunostained with anti-glial fibrillary 
acidic protein (GFAP, Dako, Glostrup, Denmark). For that purpose, astrocyte cultures 
were fixed with 4% paraformaldehyde, permeabilized with 0.2 % Triton X-100, and 
incubated with 3% normal goat serum to block nonspecific binding. Cultures were 
incubated overnight with the primary antibody at a dilution of 1:5000 in the presence of 
1.5% blocking serum. The cells were washed and incubated with Alexa Fluor 488-
conjugated secondary antibody (1:1500; Molecular Probes, Invitrogen) for 1 h. In 
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addition, cell nuclei were stained with bisbenzimide (5 μM). The number of normal 
nuclei and that of condensed and fragmented nuclei, which are indicative of apoptosis, 
was counted with the analySIS image analysis software (Soft Imaging System, Münster, 
Germany). At least two fields (1.3 mm2
 
 / field) were microphotographed for each well. 
Animals and treatments 
Male 3-month-old Sprague-Dawley rats that had been retired from breeding and 
weighed 300-350 g were purchased from Charles River (Lyon, France). They were kept 
at the University of Barcelona’s animal facility in standard conditions of temperature 
and humidity, with two animals per cage, a 12-h light, 12-h dark cycle, and food and 
water ad libitum. All handling and experimental procedures were approved by the 
Animal Ethics and Health Committees of the University of Barcelona. 
Rats were infused icv for 4 weeks through an osmotic pump (see Surgical procedures) 
either with vehicle, pro-oxidant compounds, Aβ or a combination of pro-oxidants and 
Aβ. The pro-oxidant treatment was a mixture of FeSO4 and BSO at the doses reported 
previously [33]. Aβ was administrated as a mixture of Aβ40 and Aβ42 in human high 
density lipoprotein (HDL) as a carrier, with a previous injection of 10 ng transforming 
growth factor β1 (TGFβ1) (R&D Systems, Minneanapolis, MN) into both anterodorsal 
thalamus nuclei, according to the in vivo rat model established by Frautschy and cols. 
[32]. The vehicle was HEPES 4 mM, pH 8. An additional group with the combination 
of pro-oxidants and a high dose of Aβ42 was added as a reference [33]. Therefore, rats 
were randomly assigned to one of five separate groups (6-8 animals per group): Group 
I, vehicle; Group II, 0.47 mg FeSO4 heptahydrate (1.68 µmol FeSO4) and 4.48 mg 
(20.16 µmol) BSO; Group III, 20 µg (10.1 nmol) Aβ40 and 30 µg (15.1 nmol) Aβ42 in 
80 µg HDL; Group IV, FeSO4/BSO plus Aβ40/Aβ42; Group V, FeSO4/BSO plus 50 µg 
(25.2 nmol) Aβ42. The mixture of BSO and FeSO4 
 
was prepared in distilled water and 
administrated in a separate pump from Aβ to avoid chemical interactions. The indicated 
doses are the total received at the end of the infusion period. The perfusion rate of the 
pumps was 0.25 μl/h. All animals were subjected to brain histological studies after 
completion of the long-term behavioral studies, as described below. Three or four 
animals per group were added to the study to be sacrificed immediately after the brain 
infusion treatment and analyzed by brain histology. 
Surgical procedures 
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Rats were anesthetized with a mixture of ketamine 80 mg/kg (Ketolar 50 mg/ml®, 
Pfizer, Alcobendas, Madrid, Spain) and xylazine 5 mg/kg (Rompun®, Bayer, Kiel, 
Germany) that was intraperitoneally injected. Alzet model 2004 mini-osmotic pumps 
(Alzet Osmotic Pumps, Durect Corporation, Cupertino, CA), attached via polyethylene 
tubing to brain catheters (Alzet), were filled with the treatment solutions and 
stereotactically implanted into the lateral ventricles. Animals receiving pro-oxidants and 
Aβ and controls had one minipump implanted in each lateral ventricle. The stereotactic 
coordinates were: anterior-posterior (AP) and medio-lateral (ML) to bregma -0.9 mm 
and ± 1.4 mm, respectively; dorso-ventral (DV) to dural surface: -3.5 mm. Animals 
receiving TGFβ1 were injected immediately before pump implantation at the 
coordinates of the anterodorsal thalamus nuclei: AP -2.1 mm, ML ± 1.4 mm, and DV -
4.6 mm, using a 25 G stainless steel cannula (Small Parts Inc, Miami, FL) connected to 
a Hamilton syringe through a Teflon tube. The syringe was attached to a micro-infusion 
pump (Bioanalytical systems Inc., West Lafayette, IN). The cannula was left in position 
for 5 min after delivery to prevent the solution from surging back. At the end of the 4-
week infusion period, rats were slightly anesthetized to remove the osmotic pumps. 
Pump patency and functionality were confirmed by verifying that the pump contents 
had been discharged and that the infusion apparatus was intact. 
 
Behavioral testing 
The behavioral test for spatial learning memory was performed in a Morris water maze 
(MWM). The apparatus and procedures were basically as described elsewhere [36, 37]. 
The behavioral test was initiated 4 weeks after surgery when the treatment was 
complete. A pre-training test with no landmarks and a hidden platform consisted in 4 
trials over 2 days. The rats were given 120 s to find the platform, and then allowed to 
remain on it for 30 s. Rats that did not reach the platform were picked up, placed on the 
platform and left there for 30 s. The procedure was the same in the acquisition test, but 
the animals had to rely on the landmarks to find the hidden platform. Animals were 
given 4 escape trials per day for 6 days, which amounted to a total of 24 trials. On the 
last day, a 60 s probe trial was performed with the platform removed. To analyze the 
rat’s behavior, the surface of the pool was divided into four quadrants and the time that 
the rat spent in the quadrant where the platform had previously been located was 
calculated. To monitor long-term memory, animals were submitted to a new series of 2 
escape trials followed by a 60 s probe trial at 1, 5 and 9 weeks after the end of the 
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acquisition period. Three weeks later, a new training acquisition assay of 4 escape trials 
per day for 6 days was performed with reversal of the location of the submerged 
platform. A 60 s probe trial with the platform removed was performed on the last day. 
New probe trials, preceded by 2 escape trials, were performed after 1, 2 and 4 weeks. 
The study ended 4 months after the infusion treatment. 
 
Rat brain dissection and histology 
Rats were anesthetized as described above and perfused with isotonic saline (0.9 % 
NaCl) with heparin, followed by isotonic saline and finally by buffered formaldehyde 
(4% formaldehyde in phosphate buffer 0.01 M pH 7.4). Brains were quickly removed, 
placed in a Stoelting Tissue Slicer and cut into 4 mm blocks. Tissue blocks were 
postfixed with buffered formaldehyde for 24 h, then washed with phosphate buffer for 
24 h and finally washed with water. Next they were dehydrated and embedded in 
paraffin. Paraffin-embedded blocks were sectioned at 5-7 µm and mounted on Histogrip 
(Zymed laboratories, Invitrogen) coated slides for immunostaining. Paraffin-embedded 
sections were dewaxed in xylene and rehydrated through decreasing concentrations of 
ethanol before staining. The accuracy of the cannula placement was determined by 
hematoxylin or Nissl staining. Microglia immunostaining was carried out by free 
floating 50 µm vibratome sections of non-paraffin-embedded rat brains. Antigen 
retrieval was performed by boiling the sections in 10 mM citrate buffer (pH 6) for 10 
min. When sections had cooled, they were washed in saponin 0.05% in PBS and then in 
PBS. Normal serum (horse or goat, 1:5) in 0.2 % gelatin, 0.2 % Triton X-100 in PBS 
was used at room temperature to block non-specific reactions for 2 h. Sections were 
incubated with the appropriate antibody diluted in 0.2 % Triton X-100 and normal 
serum (1:20) in PBS at 4ºC overnight. The following primary antibodies were used to 
detect specific brain tissue alterations: anti-Aβ clone 4G8 (1:150; Signet, Dedham, 
MA), anti-8-hydroxy-2’-deoxyguanosine (8OHdG) (1:50; JaICA, Nikken SEIL, 
Fukuroi, Japan), anti-GFAP (1:300; Dako), anti-ubiquitin (1:50; Novocastra, Newcastle 
upon Tyne, England) and anti-macrophage complement receptor 3 (OX42, 1:500; AbD 
Serotec, Kidlington, UK). Sections were then washed in PBS and incubated with the 
appropriate biotinylated secondary antibody for 2 h at room temperature. Tomato lectin 
histochemistry was carried out on paraffin-embedded sections overnight at 4°C using 
biotinylated lectin from Lycopersicum esculentum (2.5 μg/ml). The Vectastain ABC kit 
(Vector Laboratories, CA) was used as per manufacturer’s instructions, and the reaction 
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was visualized with diaminobenzidine containing 0.1 % H2O2
 
 for 5–10 min. Where 
required, sections were lightly counterstained with Harris’ hematoxylin. Iron deposits 
were visualized by Pearl’s Prussian blue staining and counterstaining with neutral red, 
following standard procedures. Selected paraffin sections were also stained with fluoro-
Jade B (following the protocol of the supplier, Chemicon International) to check for 
degenerating neurons and reactive astroglia [38]. Then, the tissue sections were dried, 
dehydrated through increasing ethanol concentrations and xylene, and mounted in DPX 
(Fluka, Buchs, Switzerland). Selected sections of Aβ treated rats were also stained for 
Aβ deposits with thioflavine S (1 % thioflavine S aqueous solution staining) followed 
by 70º ethanol differentiation. Then they were mounted in Mowiol (Calbiochem, Merck, 
Darmstadt, Germany). 
Data analysis 
Results are shown as mean ± SEM. Statistics was performed with one way ANOVA and 
repeated measures ANOVA for in vitro and in vivo experiments, respectively. A post 
hoc Newman-Keuls test was used for group comparison (GraphPad Prism software, 
GraphPad, San Diego, CA). 
 
 
Results 
 
In vitro oxidative stress  
Oxidative stress changes in human astrocyte cultures are shown in Fig.1. Depletion of 
glutathione by BSO did not increase the generation of hydroperoxides measured by 
DCFH-DA in normal culture conditions. Neither did Aβ exposure. The presence of 
oxidant ferrous ion from FeSO4 induced a small increase in hydroperoxide generation. 
However, a highly significant increase in DCF fluorescence was detected when both 
pro-oxidant agent treatments, BSO and FeSO4
 
, were added to Aβ exposure. 
In vitro inflammation 
A three-day treatment with a mixture of interleukin-1β and interferon-γ induced 
morphological changes and NO generation in the human astrocytes, both of which are 
indicative of an inflammatory response (Fig. 2). Unstimulated astrocytes generally 
  11 
11 
exhibited a flattened and polygonal morphology, whereas activated astrocytes showed 
thinner and elongated cytoplasm processes and spherical nuclei in a stellate-like 
morphology. No changes were evident with interleukin-1β, but interferon-γ and the 
mixed treatment of both cytokines induced a characteristic stellate morphology with 
long cytoplasmic processes (Fig. 2 A-D). The presence of nitrite formation in the 
culture medium, which is indicative of NO astrocyte generation, was also significantly 
enhanced by the mixed cytokine treatment (Fig. 2 E). The peptide Aβ did not increase 
NO over control values (3.6 ± 0.2 µM), either alone (3.3 ± 0.4 µM) or in the presence of 
pro-oxidant agents (3.4 ± 0.3 µM). Therefore, we analyzed the presence of Aβ-induced 
morphological changes, which are indicative of inflammation, in comparison to changes 
after the cytokine treatment (Fig. 3). The combined treatment of BSO, FeSO4
 
 and Aβ 
caused a clear reorganization of the human astrocyte cytoskeleton, which was similar to 
that seen with cytokines. In contrast, Aβ alone caused moderate changes (Fig. 3 A-D).  
In vitro cytotoxicity 
No cytotoxicity was caused by BSO treatment or exposure to FeSO4 or Aβ alone in 
human astrocytes. However, a small increase in condensed nuclei which are indicative 
of apoptotic cell death, was detected after the combined treatment of BSO, FeSO4
 
 and 
Aβ (Fig 3 D and E).  
In vivo toxicity 
The treatment administrated to Group IV (BSO/ FeSO4 plus Aβ42/Aβ40
 
), was highly 
toxic. Two out of 8 rats died during the experiment (and were excluded from the the 
behavioral results). Rats in this group had more dilated cerebral ventricles than the other 
animals, which suggests that they had impaired CSF drainage.  
Cognitive deterioration 
The time spent in the water maze quadrant where an escape platform has been located is 
a reliable indicator of rat learning and memory capacities in our experimental 
conditions, as discussed elsewhere [37]. Results of the probe trials for the different 
treatment groups are shown in Fig. 4. Rats infused with BSO and FeSO4 showed 
learning acquisition, a pattern of retention and a post-acquisition period that did not 
differ from that of the control animals (Fig. 4A). When the platform position was 
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changed (Fig. 4B), no differences were detected between rats treated with pro-oxidant 
agents and the control group. All the Aβ-treated groups had significantly decreased 
learning and memory (Fig. 4A and B). Reversel acquisiton clearly evidenced lower 
cognitive capacities in groups treated with the mixture of BSO/FeSO4 and Aβ, when 
either a mixture of Aβ40 and Aβ42 [32] was administered or a higher dose of Aβ42
 
 [33] 
(Fig. 4B). 
Histological alterations 
Rats receiving Aβ (Groups III, IV and V) showed brain tissue deposits that stained 
positive for anti-Aβ antibody. Groups IV and V, in which rats were infused with BSO/ 
FeSO4
We did not detect iron precipitates in the brain tissue of rats from Groups I, II and III. 
Ferric iron was barely detected in the hippocampus, septum or other areas next to the 
infused ventricle of rats treated with the mixture of BSO/FeSO
 in addition to Aβ, had much higher deposition than those in Group III. Diffuse 
plaques or precipitates were preferentially detected in areas next to the infused ventricle, 
such as corpus callosum and septum, but also in cerebral cortex, vessels and all over the 
brain. Aβ deposits were present in rats that were either immediately sacrificed after 
infusion or sacrificed at 4 months post-infusion. Brain septum presented a high density 
of Aβ precipitates mainly in Group IV. The septum is a cellular area in the rat, which 
contains neuron complexes highly interconnect with the hippocampus [39]. As 
expected, Aβ precipitates stained positive for thioflavine S (not shown). Representative 
histological images are shown in Fig. 5.  
4
Hypertrophic astrocytes that were highly reactive to anti-GFAP were mainly detected in 
rat Groups IV and V in the hippocampus, corpus callosum and frontal cortex. 
Inflammatory effects were detected at the end of the infusion and continued throughout 
the 4 months post-infusion. In the long term, Group IV astrocytes were more reactive 
than Group V. Fluoro-Jade B distinctly stained the most reactive astrocytes that were 
those in Group V rats sacrificed immediately after the infusion. Representative 
histological images are shown in Fig. 7.  
 and Aβ (mainly Group 
V), which were sacrificed after infusion. Four months later, Group IV showed extensive 
iron staining. See representative histological images in Fig. 6. 
Inflammatory effects were also shown by the presence of reactive microglia that were 
stained with anti-OX42 stain, mainly in the Group IV rats. Lectin staining showed more 
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ramified microglia in Aβ-treated groups. In the long term, Group IV rats still showed 
reactive microglia. Representative images are shown in Fig. 8. 
No neuron damage was histologically detected in the rats sacrificed immediately after 
the pump-infusion, but alterations were detected in rats sacrificed at the end of the 4 
month post infusion study. Oxidative DNA damage, as indicated by anti-8OHdG 
staining was high in Group IV and less extensive in Group V. It occurred mainly in 
hippocampal pyramidal neurons. Intraneuronal accumulation of ubiquitin and 
ubiquitinated proteins, as stained by the anti-ubiquitin antibody, was detected in neurons 
of the hippocampus and cortex of rats from Groups III and IV and was less intense in 
Group V. DNA oxidation was present in pyramidal neurons, whereas ubiquitin 
accumulation also occurred in other neuron types. Representative images are shown in 
Fig. 9. 
 
 
Discussion 
Astrocytes are generally more resistant to toxins than neurons, but they are exposed to 
Aβ damage. It is known that human astrocytes in vitro can bind and internalize Aβ42 
[40, 41], as they do in vivo. In this work, in vitro incubation with Aβ42 induced poor 
toxic effects in human astrocytes, as seen by the absence of oxidative stress and cell 
death. Only slight morphological changes were appreciable, indicating some activation 
effect. This confirms a previous report in which cultures of human astrocytes were not 
killed by Aβ40 or Aβ42, even when it was intracellularly microinjected [42]. However, 
aggregated Aβ40 was toxic to up to 50 % of the cultured rat astrocytes, probably through 
the generation of hydrogen peroxide [43], a major Aβ neurotoxicity mechanism [44]. 
Changes in intracellular Ca2+ signaling leading to mitochondrial impairment, oxidative 
stress and glutathione depletion were also reported in rat astrocyte cultures and caused 
by specific insertion of β-aggregated Aβ42 into the astrocyte plasma membrane [45]. 
Therefore rat astrocytes are more vulnerable to Aβ than human astrocytes in vitro, even 
though Aβ probably induces oxidative stress in human astrocytes. In this case, 
Aβ toxicity would increase in a pro-oxidant environment with lower antioxidant 
defense. Certainly, the toxic and inflammatory damage to human astrocytes caused by 
Aβ42 increased greatly in the presence of redox active iron and an inhibitor of 
glutathione synthesis. As expected, depletion of glutathione per se did not induce 
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oxidative stress, whereas Fe2+ and BSO/Fe2+ increased ROS generation but not cell 
death. The pro-oxidative effects of BSO and Fe2+ partially mimic the oxidative stress of 
aged brain astrocytes, with lower antioxidant defense and free radical damage [24, 25]. 
The age-related iron homeostasis disruption leads to iron increase and also contributes 
to oxidative stress in the aged brain [15]. Incubation of cultured human astrocytes with 
Aβ42 induced negligible ROS generation, which was highly significant in aged-like 
astrocytes, with impaired antioxidant defense and Fe2+
Human astrocytes in vitro show flat and polygonal morphology, even though they are 
multiple branched cells in the brain. This is also the case for murine astrocyte cultures. 
In the latter, several agents, including cytokines and Aβ, induce skeletal reorganization 
to a stellate morphology, which is indicative of activation plastic changes [46-48]. 
Treatment with IL1β  induced a stellate morphology in our human astrocyte cultures, as 
previously reported by other authors [49]. To a lesser extent, Aβ exposure caused 
morphological changes that are indicative of activation. These changes were highly 
potentiated in a pro-oxidant environment when the peptide was co-incubated with 
FeSO
-induced oxidative stress.  
4
The mixed treatment of Aβ
 in glutathione-depleted astrocytes. We did not detect an increase in nitrite 
formation after these treatments. Activated astrocytes adjacent to Aβ plaques in AD 
brain generate NO [50], whereas astrocytes in healthy brain do not. The astrocyte 
inducible enzyme NO synthase is activated by cytokines or other mediators of brain 
damage. Several authors have reported that Aβ causes NO generation in murine 
astrocyte cultures in the presence of cytokines, that are either co-incubated [51] or 
released by contaminating microglia [52]. However, the peptide alone does not cause 
NO generation [53; but see 54]. We found that cultured human astrocytes generated NO 
after incubation with cytokines, but not with Aβ. The mixture of IL1β and INFγ 
produced nitrite, as previously described [55, 56]. 
42 plus BSO and Fe2+ induced a low level of apoptotic death, 
which corroborates its toxic effects. An apoptotic pathway was also reported in cultured 
rat astrocytes, as induced by Aβ toxicity [57]. The increased sensitivity of human 
astrocytes to Aβ in the presence of iron and impaired redox homeostasis means that 
aged astrocytes are more liable to suffer Aβ damage and enter into the AD vicious cycle 
of oxidative stress and inflammation than those in young individuals. Thus, aged 
astrocytes no longer carry out their functions of synapsis modulation and vital support 
to neurons. Instead, they contribute to AD pathophysiology.  
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The icv infusion of Aβ in rat is a widely used AD model for pharmacological studies, as 
cognitive impairment and other AD-related pathologies can be reliably quantified [58, 
59]. The 4-week combined Aβ40/Aβ42 infusion in a model developed by Frautschy and 
cols. causes gliosis, deposition of Aβ and delayed cognitive impairment [32]. It has 
been suggested that infused Aβ42 induces oxidative stress and astrocytic dysfunction 
that are in the basis of the learning deficits [60]. Accordingly, we found a sustained 
decrease of cognitive abilities in the MWM. Twelve weeks after the first training, 
retention of reversal platform training was lower than in the control group, which 
indicated that long-term cognitive loss had occurred. Moderate AD related brain 
pathology was observed, as previously reported [32]. The infusion of a pro-oxidant 
treatment with BSO and Fe2+ did not show toxic effects per se throughout the entire 
study. However, when treatments Aβ40/Aβ42 plus BSO/Fe2+ were simultaneously 
administrated, both behavioral and pathological studies showed increased toxicity. 
These rats had a similar, behaviorally impaired response to the Aβ40/Aβ42 treated rats in 
the first training, but a worse response in late reversal training. Histologically, Aβ 
deposits were highly increased, astrocytes were more reactive at the end of the 
treatment and they partially maintained activation throughout the 4-month study. 
Microglia was more reactive and iron deposits were present until the end of the study. 
As regards neurons, hippocampus pyramidal neurons showed highly oxidized DNA at 4 
months after Aβ40/Aβ42 plus BSO/Fe2+, whereas intraneuronal ubiquitin accumulation 
was similar to that caused by Aβ40/Aβ42
We knew from a previous study that post-acquisition icv infusion with Aβ
 treatment. Thus, in this rat model, Aβ inhibits 
the neuronal ubiquitin proteasome system, as reported in AD patients [61, 62]. 
42 alone plus 
BSO and Fe2+ induced decreased performance in the MWM tested immediately after the 
treatment [33]. When we tested this treatment in our long-term study, we found a long 
lasting spatial memory impairment, similar to that of the group treated with Aβ40/Aβ42 
plus BSO/Fe2+. Even though both rat groups were similarly impaired behaviorally, AD 
pathology was more intense in rats infused with Aβ40/Aβ42 and BSO/ Fe2+ than in those 
with Aβ42 and BSO/ Fe2+. This could be partially related to the fact that iron deposits 
were long lasting in the first but not in the second group, where they could only be 
detected in rats sacrificed immediately after infusion. Therefore, the interaction of iron 
with different Aβ species can modulate the pathological outcome. It seems that a 
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mixture of 20 µg of Aβ40 plus 30 µg of Aβ42 [32] can lead to longer lasting effects in 
vivo than 50 µg of Aβ42 
In AD, redox active iron has been reported both intraneuronally in vulnerable neurons 
[63] and associated with amyloid plaques and neurofibrillary tangles [64]. Iron was also 
increased in the Aβ deposits of AD transgenic mice [65]. In our study we detected an 
inflammatory response in the astrocytes of rats treated with iron and Aβ, which parallels 
the in vitro effects discussed above in human astrocytes. The increased oxidative stress 
seen in these rat hippocampal neurons may be partially derived from the impaired 
antioxidant capacity of the surrounding astrocytes. Early Aβ-induced astrocyte 
derangements may contribute to neuron death by failure of antioxidant support [66]. In 
advanced stages of AD pathology, these chronic astrocyte alterations of oxidative stress 
and inflammation will further impair neuron functionality and contribute to the 
degenerative process [67, 68]. 
alone [33].  
Overall we gathered in vitro and in vivo data that further confirm the involvement of 
redox reactive iron in the development of age-related AD pathology and suggest early 
Aβ damage of frail, aged astrocytes. Therefore, the use of in vitro and in vivo aging 
models may help to understand the brain aging contribution to AD development and 
progression. In this line, Pallas and cols. have suggested that the use of the previously 
mentioned SAMP8, senescent mice with some incipient AD traits, may help to unveil 
“the switch” from aging to AD [69]. 
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Figure legends 
 
 
 
Fig. 1. Oxidative stress in human astrocyte cultures is increased by Aβ in pro-oxidant 
conditions. Treatment with Aβ42 alone did not generate reactive oxygen species, but 
Aβ42 potentiated the effect of pro-oxidant agents. Astrocytes were incubated with Aβ42 
20 μM (Aβ42), FeSO4 25 μM (Fe) and buthionine sulfoximine 1mM (BSO) for 4 h at 
37ºC. BSO was added 24 h before the addition of Aβ 42 and FeSO4
 
. The reactive oxygen 
species generation was assayed by dichlorofluorescein (DCF) formation. Results are 
shown as the mean ± SEM from duplicate determinations in four different cultures. 
Statistics: *p<0.05, **p<0.01 and ***p<0.001 as compared to control.  
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Fig. 2. Cytokine treatment causes activation of human astrocytes. Cultured astrocytes 
changed its polygonal shape to a smaller spherical body with long filamentous 
prolongations, known as stellate morphology, in the presence of active cytokines. 
Astrocyte morphology was visualized in astrocytes fixed with 4 % paraformaldehyde 
and stained with anti-GFAP antibody. Images show control astrocytes, and astrocytes 
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exposed to interleukin-1β 10 ng/ml (IL-1β), interferon-γ 10 ng/ml (IFN-γ) or both for 3 
days. Arrows indicate long cytoplasmic processes characteristic of the activated stellate 
morphology. Scale bar: 20 µm. E) Nitrite accumulation in the respective culture media 
was measured using the Griess reagent. Results are shown as the mean ± SEM of four 
determinations from two different cultures. Statistics: *p<0.001 as compared to control. 
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Fig. 3. Pro-oxidant conditions trigger the toxic and inflammatory effects of Aβ in 
human astrocyte cultures. Treatment with Aβ42 alone caused a barely distinguishable 
change to an activated morphology. However, the mixed treatment with Aβ42 and pro-
oxidant agents caused astrocyte activation and apoptosis.  A) Astrocytes were stained 
with anti-GFPA antibody and nuclei were counterstained with bisbenzimide. Images 
show control astrocytes, as well as astrocytes exposed to FeSO4 10 μM (Fe) plus 
buthionine sulfoximine 1mM (BSO), those exposed to Aβ42 5 μM (Aβ42), and those 
exposed to both treatments, for 3 days. BSO was added 24 h before the addition of Aβ42 
and FeSO4
 
. Scale bar: 20 µm. B) The number of condensed and fragmented nuclei was 
recorded for the different treatments, as labeled in the graph. Results are shown as the 
mean ± SEM of three to five determinations from two different cultures. Statistics: 
*p<0.05 as compared to control.  
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Fig. 4. In vivo treatment with Aβ causes a decreased cognitive capacity that is 
potentiated by pro-oxidant agents in adult rats. Cognitive behavioral testing in the 
Morris water maze of rats administrated with Aβ and a pro-oxidant treatment showed 
long term cognitive loss. Pro-oxidant agents alone did not induce any effect on rat 
behavior. Rats were previously administrated icv for 4 weeks with: I, a vehicle 
(Control); II, a pro-oxidant treatment of 4.48 mg buthionine sulfoximine and 0.47 mg 
FeSO4 heptahydrate (BSO/Fe); III, a mixture of 20 µg Aβ40 and 30 µg Aβ42 
(Aβ40/Aβ42); IV, pro-oxidant treatment plus Aβ40 and Aβ42 mixture (Aβ40/Aβ42 + 
BSO/Fe); and V, a pro-oxidant plus a high Aβ42 treatment of 50 µg (Aβ42 + BSO/Fe). 
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A) Probe trials performed after a 6 day acquisition period (week 0) and thereafter at 1, 5 
and 9 weeks later. An initial stronger effect was seen in the group V as compared to the 
group IV. B) Probe trials performed after a reversal platform acquisition, initiated 3 
weeks after the previous behavioral study at the end of acquisition (week 0) and 1, 2 and 
4 weeks later. In the long term, both groups dosed with Aβ plus pro-oxidants (IV and V) 
showed similarly high deleterious effects on cognition. Dotted lines indicate chance 
performance. Statistics: *p<0.05, **p<0.01, ***p<0.001 as compared to the indicated 
experimental group. 
 
 
 
Fig. 5. Pro-oxidant agents potentiate brain Aβ accumulation. Aβ precipitates were found 
scattered in the brain tissue near the ventricular area where it was infused. Vessels also 
stained positive for Aβ. The long term Aβ accumulation was higher in the groups 
simultaneously dosed with pro-oxidant agents. Immunohistochemistry was performed 
with anti-Aβ antibody 4G8 and nuclei were lightly counterstained with hematoxylin. A-
D) Representative images of cerebral cortical capillary blood vessels in animals 
  30 
30 
sacrificed after the infusion period. E-P) Representative images of frontal cortex, corpus 
callosum and septum of animals sacrificed at the end of the study, 4 months post 
treatment. Arrows point to Aβ deposits and Aβ positive capillary vessels. For details of 
treatment groups see the legend to Fig. 4. Scale bar = 20 µm.  
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Fig. 6. Brain iron accumulation was caused by Aβ treatment. Accumulated ferric iron 
was barely present in the brain rat after the infusion period and only in the group dosed 
with Aβ42 + BSO/Fe. However, 4 months later, the rats dosed with Aβ40/Aβ42
 
 + 
BSO/Fe showed extensive iron accumulation. Histochemistry was performed with 
Pearl’s Prussian blue and tissue was counterstained with neutral red. A-D) Pyramidal 
layer of hypocampus CA1 of rats sacrificed at the end of the infusion period. E-H) 
Septum of rats sacrificed at the end of the study, 4 months later. Arrows point to intra 
and extracellular precipitates. For details of treatment groups see the legend to Fig. 4. 
Scale bar = 20 µm in A- D and 40 µm in E-H.  
 
 
Fig. 7. Pro-oxidant agents potentiate astrocyte activation induced by Aβ  treatment. 
Immediately after treatment, the higher astrocyte reactivity was caused by Aβ42 + 
BSO/Fe, where astrocytes also stained positive for Fluoro-Jade B. Long term reactive 
astrocytes were mainly observed in rats treated with Aβ40/Aβ42 + BSO/Fe. A-D) Images 
of immunohistochemistry with anti-GFPA antibody and light counterstain with 
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hematoxylin in hippocampus Ammon’s horn of rats sacrificed immediately after the 
infusion treatment. E-H) Fluoro-Jade B fluorescence staining of the same brain area and 
treatment groups than the previous images, as indicated. I-P) GFAP immunostaining in 
frontal cortex and corpus callosum of rats sacrificed at the end of the study, 4 months 
post treatment. Arrows point to reactive astrocytes. For details of treatment groups see 
the legend to Fig. 4. Scale bar = 80 µm in A-H and 20 µm in I-P. 
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Fig. 8. Pro-oxidant agents potentiate microglia activation induced by Aβ  treatment. 
Treatment with Aβ40/Aβ42
 
 + BSO/Fe caused microglia reactivity that was maintained 
up to the end of the study, 4 months after treatment. The other Aβ treatments assayed 
caused short time reactivity. A-D) Microglia staining with Lycopersicum esculentum 
lectin hystochemistry and light counterstain with hematoxylin in frontal cortex of rats 
sacrificed immediately after treatment. E-H) Immunostaining of reactive microglia with 
anti-OX42 in the corpus callosum of rats sacrificed at the end of the study. Arrows 
indicate reactive microglia. For details of treatment groups see the legend to Fig. 4. 
Scale bar = 20 µm in A-D and 40 µm in E-H. 
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Fig. 9. Brain neurons suffer a delayed damage after Aβ and pro-oxidant agent treatment. 
Neuronal damage was not detected histologically in the early sacrificed rats, but only at 
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the long term period assayed at 4 months post treatment. A-D) DNA oxidation, as 
indicated by staining with anti-8-OHdG antibody, was caused by Aβ40/Aβ42 + BSO/Fe 
and in minor degree by Aβ42 + BSO/Fe. E-H) Proteasome system dysfunction, as 
indicated by anti-ubiquitin antibody staining of intraneuronally accumulated ubiquitin, 
was caused by Aβ40/Aβ42 in the presence or absence of pro-oxidants. After 
immunohistochemistry, tissue was lightly counterstained with hematoxylin. Arrows 
point to damaged pyramidal neurons. For details of treatment groups see the legend to 
Fig. 4. Scale bar = 20 µm. 
